Clinical Outcomes of Left Atrial Appendage Occlusion Versus Switch of Direct Oral Anti-coagulant in Atrial Fibrillation

Study Population and Design

This is a cohort study of AF patients undergoing LAAO in all eight public hospitals that performed the procedure in Hong Kong compared with a propensity score–matched control cohort of AF patients with a first switch from one DOAC (dabigatran, rivaroxaban, apixaban, edoxaban) to another DOAC between January 1, 2012 and December 31, 2020. Patients were identified and their baseline characteristics, exposures and outcomes were retrieved from the Clinical Data and Analysis Reporting System (CDARS). CDARS is a territorial-wide electronic health record managed by the Hospital Authority of Hong Kong, which provides hospital care to approximately 90% of the local population as public health service. CDARS records all essential clinical information including patients’ demographics, hospitalisation, visits to out-patient clinics and emergency services, diagnoses, laboratory results, procedures, prescriptions, dispensing of medications and death. Patients were anonymized while clinical data can be retrieved from CDARS with a unique, anonymous patient identifier. Many high-quality, population-based studies and multinational pharmacovigilance studies have been conducted based on the data retrieved from CDARS.¹⁴ The International Classification of Diseases, Ninth Revision (ICD-9), was used for disease coding and previous studies have verified the accuracy of the coding in CDARS with high positive and negative predictive values of more than 90%.^15,16 Patients’ management and follow up were per routine usual care at the discretion of managing physicians. The study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority.

We included all adult patients (18 years of age or older) with paroxysmal, persistent, or permanent non-valvular AF or atrial flutter, CHA2DS2-VASc ≥2, and underwent either LAAO or DOAC switch. The date of LAAO or first prescription of the new DOAC was used as the index date. Patients were excluded if they have any mechanical heart valves, significant mitral stenosis, an indication for anti-coagulation therapy other than AF, any recent stroke or thromboembolic event within 30 days before index date.

Definitions of Exposure and Outcome Variables

The primary outcome was a composite of all-cause mortality, ischemic stroke and major bleeding. The secondary outcomes were individual components of the primary outcome, cardiovascular mortality. Major bleeding was defined as a composite of fatal bleeding event, intracranial or intraocular bleeding, bleeding necessitating transfusion, or bleeding that caused a drop in hemoglobin of ≥3g/dL, or bleeding that required surgical intervention for control, corresponding to type 3 or type 5 bleeding according to the Bleeding Academic Research Consortium Definition for Bleeding.¹⁷

Statistical Analyses

All analyses were performed with prespecified endpoints and statistical methods. We constructed a propensity score that predicted the likelihood of LAAO versus DOAC switch with variables selected based on components of CHA2DS2-VASc, HAS-BLED scores: congestive heart failure, hypertension, age, diabetes mellitus, ischemic stroke or transient ischemic attack, peripheral vascular disease or history of myocardial infarction, female sex, abnormal liver test, estimated glomerular filtration rate (eGFR), history of major bleeding, baseline anemia (hemoglobulin <13g/dL for men and <12g/dL for women), concomitant use of anti-platelet or non-steroidal anti-inflammatory agent, chronic alcoholism.

The study cohort consisted of two comparison groups – “LAAO group” and “DOAC switch group” – generated by 1:2 propensity-score-matching using a caliper of 0.2 times the standard deviation of the logit of the propensity score. We adopted complete case analysis to handle the very rare occurrence of missing variables. Unadjusted analyses were made using chi-square tests for categorical variables and Student’s t-test or Wilcoxon rank-sum tests for continuous variables. Kaplan-Meier survival curves were constructed for study groups.¹⁸ Cox proportional hazards regression was performed to evaluate the relationship between exposure and clinical outcomes as a time-to-first-event analysis with administrative censoring at 3 years after the index date, loss to follow up or end of study (July 31, 2021). Since anti-thrombotic therapy is typically de-escalated (e.g. cessation of dual anti-platelet therapy) at 6 months after LAAO, we performed additional landmark analysis for events occurring after 6 months.

Sensitivity analyses

First, we included all patients before propensity score matching, and used cox regression model to evaluate the primary and secondary outcomes, using the same set of co-variates used in construction of the propensity score model in the primary analysis. Next, since patients with cancer may be less likely to receive LAAO due to perceived limited life expectancy, we repeated the propensity score matching and primary analysis in which all patients with a history of cancer at baseline were excluded, similar to previous study.¹³ Next, since patients undergoing LAAO or DOAC switch due to a prior bleeding event may differ from those without such event, we repeated the primary analysis restricted to patients with a prior history of bleeding.

Data management and statistical analyses were performed in Stata software, version 16 (StataCorp, College Station, Texas). A two-tailed P value of less than 0.05 was considered statistically significant.

Patients and Characteristics

Between January 2012 and December 2020, a total of 8,647 patients were considered for inclusion: 1375 (16.0%) were excluded due to any of the following exclusion criteria – thromboembolism within 30 days prior to index date, intracranial hemorrhage within 30 days prior to index date, having an indication for anti-coagulation other than AF, CHA2DS2-VASc score <2. Of the remaining 7,074 patients analysed, 2 were excluded due to missing value (Figure 1). Only 1 (0.04%) patient was lost to follow up, who was in the LAAO group. Baseline characteristics of all patients before propensity score matching is shown in Table S1 of the Supplementary Appendix. A total of 2,350 patients (874 in the LAAO group and 1,476 in the DOAC switch group) were generated by 1:2 propensity score matching. The mean age was 75.9 ± 8.7, in which 1,001 (42.6%) were women. The two groups were well balanced in the bassline characteristics with standardized differences less than 0.1 for all variables except for sex, prior PCI, prior bleeding event and drugs, as shown in Table 1. The most common indication for LAAO was a high HAS-BLED score ≥3 (93.2%) including more than 40% with a history of prior bleeding event (Table S2 in the Supplementary Appendix). In the LAAO group, 642 (73%) received follow up imaging study of left atrial appendage, most commonly with trans-esophageal echo.

• Download figure
• Open in new tab

Figure 1.

Study profile.*

eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention.

Primary outcomes

The mean follow up period was 1052 ± 694 days. In the propensity match cohort, the primary outcome developed in 215 (24.6%) patients in the LAAO group and in 335 (22.6%) patients in the DOAC switch group, corresponding to an annualized risk of 11.5% and 12.8% respectively (hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.80 to 1.12; P=0.516) (Table 2). Figure 2 shows the Kaplan-Meier event curves, which the LAAO group had a steeper curve in the early period but the DOAC group caught up in the later period. Kaplan-Meier event curves with landmark at 6 months were shown in Figure S1 in the Supplementary Appendix.

• Download figure
• Open in new tab

Figure 2.

Estimated probabilities of primary composite outcome.

The risk of primary composite outcome (all-cause mortality, ischemic stroke, and major bleeding) were similar between groups. Abbreviations: DOAC, direct oral anti-coagulant; LAAO, left atrial appendage occlusion

Secondary outcomes

The LAAO group had a lower all-cause mortality (HR, 0.49; 95% CI, 0.39 to 0.60; P<0.001) and cardiovascular mortality (HR, 0.49; 95% CI, 0.32 to 0.73; P<0.001) (Table 2). Both groups had similar risk of ischemic stroke (HR, 0.83; 95% CI, 0.63 to 1.10; P=0.194). Overall major bleeding was similar between groups (HR, 1.18; 95% CI, 0.94 to 1.48, P=0.150), but the LAAO group had a lower risk of major bleeding after 6 months (HR 0.71; 95% CI 0.51 to 0.97; P=0.032). Figure 3 shows the Kaplan-Meier event curves for secondary outcomes. Kaplan-Meier event curves with landmark at 6 months were shown in Figure S2-S5 in the Supplementary Appendix.

• Download figure
• Open in new tab

Figure 3.

Estimated probabilities of secondary outcomes.

Left atrial appendage occlusion group had lower risks of all-cause mortality and cardiovascular mortality, but similar risks of ischemic stroke and major bleeding.

Sensitivity analyses

Using Cox regression model to assess the outcomes in all patients before propensity score matching, the primary outcome occurred in similar frequency in both groups (HR, 0.92; 95% CI, 0.78 to 1.08; P=0.31). The LAAO had lower risks of all-cause mortality and cardiovascular mortality, but similar risks of ischemic stroke and major bleeding (Table S3 in the Supplemental Appendix). These results were consistent with the primary analysis. Next, after exclusion of patients with a history of cancer, 784 patients in the LAAO group was propensity score matched with 1,315 patients in the DOAC switch group. The primary outcome occurred in similar frequency in both groups (HR, 0.96; 95% CI, 0.80 to 1.15; P=0.63), and all secondary outcomes were consistent with the primary analysis (Table S3 and S4 in the Supplemental Appendix). Next, after restricting the analysis to patients with a prior history of bleeding, the primary outcome occurred in similar frequency in both groups (HR, 0.95; 95% CI, 0.75 to 1.21; P=0.69) (Table S5 in the Supplemental Appendix). Secondary outcomes were also consistent with the primary analysis.

Safety outcomes of LAAO and patterns of anti-thrombotic therapy

In the 874 patients underwent LAAO, 22 (2.5%) patients had procedurally related major complications, including 19 (2.2%) with pericardial effusion and/or cardiac tamponade, 7 (0.8%) with vascular complications requiring open or endovascular repair and 1 (0.1%) with device embolization. Approximately half of the patients in the LAAO group were prescribed on anti-coagulation therapy upon hospital discharge (Table 3). The median duration of anti-coagulation therapy in the LAAO group was 74 days (Interquartile range, 42 – 155 days). Almost all (93.9%) were free from anti-coagulation therapy at 6 months, but more than half (58.9%) still remained on dual anti-platelet therapy (Table 3). In the DOAC switch group, a significant portion (17.7%) discontinued anti-coagulation therapy at 6 months.